"The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresect"...
Phosphocol Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Phosphocol P 32 (chromic phosphate P 32) Suspension is a diagnostic agent used for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include transitory radiation sickness, bone marrow depression, inflammation of the lining of the lungs or the abdominal lining, nausea, and abdominal cramping.
The suggested dose range of Phosphocol P 32 employed in the average patient (70 kg) is: Intraperitoneal instillation: 370 to 740 megabecquerels (10 to 20 millicuries); Intrapleural instillation: 222 to 444 megabecquerels (6 to 12 millicuries); Doses for interstitial use should be based on estimated gram weight of tumor, about 3.7 to 18.5 MBq/gm (0.1 to 0.5 mCi/gm). Phosphocol P 32 may interact with other drugs. Tell your doctor all medications and supplements you use. Phosphocol P 32 is generally not recommended for use during pregnancy or while breastfeeding. Tell your doctor if you are pregnant or breastfeeding before starting treatment with Phosphocol P 32.
Our Phosphocol P 32 (chromic phosphate P 32) Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Phosphocol FDA Prescribing Information: Side Effects
Untoward effects may be associated with use of chromic phosphate P 32. These include transitory radiation sickness, bone marrow depression, pleuritis, peritonitis, nausea and abdominal cramping. Radiation damage may occur if accidentally injected interstitially or into a loculation.
The following adverse reactions associated with the use of Phosphocol P 32 have been identified during post approval use:
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Phosphocol (Phosphocol)
Additional Phosphocol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.